A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Nivolumab (Primary) ; RRx 001 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms PRIMETIME
- Sponsors EpicentRx
- 18 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.